Compare AbCellera Biologics Inc (ABCL) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? AbCellera Biologics Inc trades at $9.7 (market cap $2.99B), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.41 (market cap $78.85B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 26.4× AbCellera Biologics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MDLZ | |
|---|---|---|
Market Cap | $2.99B | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $64.99 |
52-Week Low | $2.78 | $51.51 |
Enterprise Value | $2.58B | $99.19B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
MDLZ trades at $61.53, down 1.72% today, with a bullish technical outlook supported by moving averages and oversold RSI signals. The company reported strong Q2 2026 earnings, beating estimates with $0.73 EPS and raising organic sales guidance, driven by growth in emerging markets. Valuation ratios like P/E of 37.75 and P/S of 4.01 reflect premium pricing, while profitability remains solid with an 8.86% net income margin.
The stock offers upside to the $70.50 consensus price target, supported by analyst optimism and institutional buying, but faces risks from reliance on international sales and margin pressures. Earnings momentum and dividend stability provide a favorable outlook, though macroeconomic volatility could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
